| Current status of local therapy in malignant gliomas—a clinical review of three selected approaches TA Juratli, G Schackert, D Krex Pharmacology & therapeutics 139 (3), 341-358, 2013 | 167 | 2013 |
| Early hemorrhagic progression of traumatic brain contusions: frequency, correlation with coagulation disorders, and patient outcome: a prospective study TA Juratli, B Zang, RJ Litz, KH Sitoci, U Aschenbrenner, B Gottschlich, ... Journal of neurotrauma 31 (17), 1521-1527, 2014 | 142 | 2014 |
| IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas TA Juratli, M Kirsch, K Robel, S Soucek, K Geiger, R von Kummer, ... Journal of neuro-oncology 108, 403-410, 2012 | 136 | 2012 |
| Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases PN Harter, S Bernatz, A Scholz, PS Zeiner, J Zinke, M Kiyose, S Blasel, ... Oncotarget 6 (38), 40836, 2015 | 129 | 2015 |
| Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas TA Juratli, C Thiede, MVA Koerner, SS Tummala, D Daubner, ... Oncotarget 8 (65), 109228, 2017 | 107 | 2017 |
| Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis C Mirian, AK Duun-Henriksen, T Juratli, F Sahm, S Spiegl-Kreinecker, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (4), 378-387, 2020 | 103 | 2020 |
| The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas TA Juratli, M Kirsch, K Geiger, B Klink, E Leipnitz, T Pinzer, S Soucek, ... Journal of neuro-oncology 110, 325-333, 2012 | 97 | 2012 |
| Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups TA Juratli, SS Tummala, A Riedl, D Daubner, S Hennig, T Penson, A Zolal, ... Journal of neuro-oncology 141, 327-335, 2019 | 90 | 2019 |
| DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome TA Juratli, D McCabe, N Nayyar, EA Williams, IM Silverman, SS Tummala, ... Acta neuropathologica 136, 779-792, 2018 | 80 | 2018 |
| Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic EA Williams, S Santagata, H Wakimoto, GM Shankar, FG Barker, R Sharaf, ... Acta neuropathologica communications 8, 1-10, 2020 | 77 | 2020 |
| TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study TA Juratli, S Stasik, A Zolal, C Schuster, S Richter, D Daubner, MA Juratli, ... Clinical Cancer Research 24 (21), 5282-5291, 2018 | 72 | 2018 |
| Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations TA Juratli, PS Jones, N Wang, M Subramanian, SJB Aylwin, Y Odia, ... Cancer 125 (17), 2910-2914, 2019 | 68 | 2019 |
| Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas MR Strickland, CM Gill, N Nayyar, MR D'Andrea, C Thiede, TA Juratli, ... Journal of neurosurgery 127 (2), 438-444, 2017 | 66 | 2017 |
| Peripheral nerve field stimulation for trigeminal neuralgia, trigeminal neuropathic pain, and persistent idiopathic facial pain J Klein, S Sandi-Gahun, G Schackert, TA Juratli Cephalalgia 36 (5), 445-453, 2016 | 64 | 2016 |
| Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme A Seidlitz, T Siepmann, S Löck, T Juratli, M Baumann, M Krause Radiation Oncology 10, 1-10, 2015 | 54 | 2015 |
| Genotype-targeted local therapy of glioma GM Shankar, AR Kirtane, JJ Miller, H Mazdiyasni, J Rogner, T Tai, ... Proceedings of the National Academy of Sciences 115 (36), E8388-E8394, 2018 | 51 | 2018 |
| Accelerated progression of IDH mutant glioma after first recurrence JJ Miller, F Loebel, TA Juratli, SS Tummala, EA Williams, TT Batchelor, ... Neuro-oncology 21 (5), 669-677, 2019 | 49 | 2019 |
| IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy O Uckermann, W Yao, TA Juratli, R Galli, E Leipnitz, M Meinhardt, E Koch, ... Journal of Neuro-Oncology 139, 261-268, 2018 | 49 | 2018 |
| A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas S Fujio, TA Juratli, K Arita, H Hirano, Y Nagano, T Takajo, K Yoshimoto, ... Neurosurgery 85 (2), 204-210, 2019 | 42 | 2019 |
| Real-Time Label-Free Embolus Detection Using In Vivo Photoacoustic Flow Cytometry MA Juratli, YA Menyaev, M Sarimollaoglu, ER Siegel, DA Nedosekin, ... PLoS One 11 (5), e0156269, 2016 | 42 | 2016 |
Hiroaki WakimotoMassachusetts General Hospital, Harvard Medical School在 mgh.harvard.edu 的电子邮件经过验证
